<DOC>
	<DOCNO>NCT01408472</DOCNO>
	<brief_summary>Ciliary Neurotrophic Factor ( CNTF ) demonstrate multiple pre-clinical model enhance survival regeneration retinal ganglion cell , retinal neuron injured disease like glaucoma . We hypothesize CNTF delivery human eye provide neuroprotection ( prevent loss vision ) neuroenhancement ( improve vision index ) glaucoma . Patients trial receive NT-501 CNTF implant ( make Neurotech ) one eye , carefully follow evaluate safety efficacy .</brief_summary>
	<brief_title>NT-501 CNTF Implant Glaucoma : Safety , Neuroprotection Neuroenhancement</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<criteria>must understand sign informed consent must medically able undergo ophthalmic surgery NT501 device insertion possible removal , well test require . diagnosis glaucoma characterize ( ) clinical evidence progressive RGC dysfunction degeneration use visual field least one structural modality ; ( b ) residual visual field preservation include bestcorrected visual acuity ( BCVA ) well 20/100 ; ( c ) failure contain glaucomatous progression maximally tolerate reduction intraocular pressure ( IOP ) , OR visual field defect affect fixation , reduce BCVA 20/100 . corneal , lens , optic nerve retinal disease cause vision loss , blind one eye requirement acyclovir and/or relate product study receive systemic steroid immunosuppressive medication . pregnant lactating . consider immunodeficient know history human immunodeficiency virus ( HIV ) chemotherapy , history malignancy , UNLESS treat successfully 2 year prior inclusion trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>